This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
POU2F1 / POU domain, class 2, transcription factor 1 · IHC design guide
Design Immunohistochemistry for POU2F1
Plan chromogenic POU2F1 IHC around nuclear staining in most cells (HPA tissue IHC). Colon endocrine cells show high staining, while adipocytes have no detectable staining; use these patterns to guide control selection and cell-specific scoring (HPA tissue IHC).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
POU2F1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Nuclear staining in most cells (HPA tissue IHC) | |
| Staining pattern | Nuclear signal across most cell types (HPA tissue IHC) | |
| Antigen retrieval | EDTA pH 8.0 HIER, heat-mediated (datasheet M01766-1) | |
| Positive control | Colon+4 more · see all | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections (standard IHC practice; not target-specific) | |
| Caveat | Adipocytes have no detectable staining (HPA tissue IHC) | |
| Regulation | Isoform 2 is lymphocyte-specific (UniProt) | |
| Isoform / epitope | 6 isoforms; verify epitope coverage across variants (UniProt) |
Section 1
Recommended POU2F1 IHC & IF Protocols
The catalog antibody’s IHC-P protocol uses EDTA pH 8.0 retrieval (datasheet). The published protocols below describe POU2F1 staining in lung tumors, cardiac tissue and tumors (PMC10183409; PMC13543148; PMC13097874).
| Sample | Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M01766-1) |
| Fixation | Image fixative and duration unreported (datasheet M01766-1); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: EDTA pH 8.0 (datasheet M01766-1); 20 min, 95–100 °C (standard) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet M01766-1) |
| Primary antibody | Rabbit monoclonal (clone 19P20) anti-POU2F1, 1:50 recommended; image 2 μg/ml (datasheet M01766-1) |
| Primary incubation | Overnight at 4 °C (datasheet M01766-1) |
| Detection | HRP-conjugated secondary, DAB chromogen (datasheet M01766-1) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | POU2F1-positive staining in endocrine cells of colon (HPA tissue IHC: High). HPA tissue profile: Nuclear expression in most cells. No signal in the no-primary control. |
💡Decision noteStart with EDTA pH 8.0 for the catalog antibody (datasheet). The cardiac tissue protocol used EDTA pH 8.0; the tumor protocol used 10 mM sodium citrate (PMC13543148; PMC13097874).
Section 2
What Is the Expected POU2F1 Staining Pattern?
POU2F1 is a nuclear transcription factor with no transmembrane segment (UniProt P14859: nucleus, topology). In paraffin sections, expect nuclear staining across many cell types, with particularly high reported staining in colon and rectal endocrine cells, kidney collecting ducts, placental syncytiotrophoblast cell bodies, and preleptotene spermatocytes (HPA tissue IHC: nuclear expression in most cells; High in listed populations). HPA rates the tissue pattern Supported, with medium consistency between staining and RNA data (HPA tissue IHC: reliability).
| Distinct nuclear chromogen in colon or rectal endocrine cells and kidney collecting ducts. | This fits the expected compartment and examples rated High; judge staining in the named cells, rather than assuming every cell should stain equally (HPA tissue IHC: nuclear expression in most cells; High in listed populations). |
| Predominantly cytoplasmic or membrane staining with little nuclear signal in an otherwise positive region. | This is discordant with the main tissue IHC pattern and UniProt localisation; check morphology and controls before calling it POU2F1 (HPA tissue IHC: nuclear expression; UniProt P14859: nucleus, no transmembrane segment). |
| Strong staining of adipocytes, cardiomyocytes, or skeletal myocytes. | Those populations are reported Not detected; unexpected signal warrants a check for antibody cross-reactivity or endogenous detection activity, but staining alone cannot identify its cause (HPA tissue IHC: Not detected in listed populations; standard IHC practice). |
| Diffuse chromogen across tissue and spaces between cells, obscuring nuclei. | The pattern cannot be scored confidently against a nuclear target; inspect reagent-only and tissue controls for background before interpreting cell-specific staining (UniProt P14859: nucleus; standard IHC practice). |
| No nuclear signal in an adequately preserved colon endocrine-cell or kidney collecting-duct region. | These are reported High examples, so a blank result needs an assay-control review; it does not by itself prove absence of POU2F1 in the specimen (HPA tissue IHC: High in listed populations; standard IHC practice). |
💡Expected POU2F1 appearanceCall a positive result when chromogen is clearly nuclear in the relevant cells, especially populations reported High, while treating strong cytoplasmic-only staining or staining of reported Not detected populations as findings that need control checks (HPA tissue IHC: nuclear pattern and cell-level ratings; UniProt P14859: nucleus).
| Cell-level distribution | HPA reports nuclear expression in most cells, yet ratings differ by population: colon endocrine cells and kidney collecting ducts are High, breast glandular cells are Medium, and adipocytes are Not detected; score the identified cells, not a whole-section average (HPA tissue IHC: profile and cell-level ratings). |
| Antibody evidence | HPA rates tissue IHC reliability Supported with medium staining–RNA consistency; HPA064323 and CAB002608 each have IHC Supported status, which should not be assumed to validate a different catalog antibody (HPA tissue IHC: reliability; HPA antibody validation). |
| Isoforms | UniProt lists 6 isoforms and describes isoform 2 as lymphocyte-specific; without an antibody epitope or isoform-specific staining evidence, an unexpected cell result cannot be assigned to a particular isoform (UniProt P14859: isoforms, tissue specificity). |
| IF/ICC Q: Does a cytoplasmic signal match? | A: HPA places POU2F1 mainly in the nucleoplasm in ICC-IF and also reports approved endoplasmic-reticulum and vesicle locations; those ICC-IF observations do not establish that cytoplasmic-only chromogen is the expected tissue IHC result (HPA subcellular ICC-IF; HPA tissue IHC: nuclear pattern). |
| Situation | Likely cause | Next action |
|---|---|---|
| No staining in a known-positive region. | Assay failure is possible when the identified colon endocrine cells or kidney collecting ducts are blank; the observation alone does not locate the failed step (HPA tissue IHC: High in listed populations; standard IHC practice). | Confirm the cell population and tissue preservation, then review the IHC-validated antibody, detection reagents, and matched positive control under the run's documented conditions (standard IHC practice). |
| Only cytoplasmic or membrane staining appears. | This conflicts with the expected nuclear tissue pattern, although staining location alone cannot establish the source of the signal (HPA tissue IHC: nuclear expression; UniProt P14859: nucleus, no transmembrane segment). | Recheck the counterstain and cell boundaries; compare with a reagent-only control and a positive region before scoring nuclei (standard IHC practice). |
| Unexpected signal appears in reported negative cells. | Cross-reactivity or endogenous detection activity is possible in adipocytes or muscle cells rated Not detected; the HPA rating is an observation, not proof that every specimen is negative (HPA tissue IHC: Not detected in listed populations; standard IHC practice). | Check a reagent-only control and compare nuclear staining in a reported positive cell population before attributing the signal to POU2F1 (HPA tissue IHC: nuclear pattern and High examples; standard IHC practice). |
| Diffuse background hides nuclear boundaries. | Nonspecific reagent retention or endogenous chromogenic activity may obscure the expected nuclear pattern (standard IHC practice; UniProt P14859: nucleus). | Review blocking, washing, and the detection-control result; adjust the run using the antibody's documented IHC conditions and rescore only distinguishable nuclei (standard IHC practice). |
| A positive region stains weakly. | A weak result is difficult to judge without a matched control, and HPA's High rating does not specify an intensity threshold for this assay (HPA tissue IHC: High in listed populations; standard IHC practice). | Compare the same cell type with a positive control from the run, then review the documented primary-antibody and detection conditions before assigning a negative score (standard IHC practice). |
| Different cell populations within one section receive conflicting scores. | A section-wide score can hide the reported cell-level differences, including High, Medium, and Not detected populations (HPA tissue IHC: cell-level ratings). | Identify and score each relevant population separately, recording compartment and intensity; use HPA cell-level examples as context rather than a universal cutoff (HPA tissue IHC: profile and cell-level ratings; standard IHC practice). |
Experiment evidence
IHC & IF images showing POU2F1 staining
M01766-1 · IHCIHC analysis of OCT1/POU2F1 using anti-OCT1/POU2F1 antibody (M01766-1) . OCT1/POU2F1 was detected in a paraffin-embedded section of human br
M01766-1 · IHCIHC analysis of OCT1/POU2F1 using anti-OCT1/POU2F1 antibody (M01766-1) . OCT1/POU2F1 was detected in a paraffin-embedded section of human st
PB9317 · IHCAnti-Oct-1 vendor antibody, PB9317, IHC(P) IHC(P): Human Tonsil Tissue
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/cerebral+cortex#imid_17775711
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/colon#imid_17775621
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/liver#imid_17775630
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000143190-POU2F1/tissue/kidney#imid_17775639
HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA028256; green = POU2F1, blue = nucleus, red = microtubules.
HPA · ICC-IF AF22Human Protein Atlas immunofluorescence, AF22, antibody HPA028256; green = POU2F1, blue = nucleus, red = microtubules.
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for POU2F1 IHC & IF
🧪Run kidney first and assess nuclear staining in collecting duct cells (HPA: High in collecting ducts; UniProt: nucleus). Use heart muscle cardiomyocytes as the negative tissue (HPA: Not detected in cardiomyocytes); on the kidney slide, treat cells outside collecting ducts that lack nuclear staining as internal background checks, not as proven POU2F1-negative cells (UniProt: ubiquitous).
Positive control tissue: Colon (Endocrine cells, HPA High)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show POU2F1 in AF22, CACO-2, HAP1, A-431, U2OS, SH-SY5Y, with annotated localisation: Nucleoplasm (approved) (HPA subcellular).
Technical controls: Include a no-primary (secondary-only) control, a rabbit IgG isotype control matched to the primary antibody’s clonality, and validated POU2F1 knockout material or a peptide-block control if the immunogen peptide is available (caption: rabbit primary; standard IHC controls). Check kidney sections for endogenous peroxidase before interpreting DAB staining, and block it if present (standard IHC practice; HPA: kidney collecting ducts High).
⚠️Feasibility: A target-specific fixation window or fixation effect is unreported, and the selected M01766-1 paraffin-section caption does not state a fixative (caption: fixative not stated). The demonstrated IHC procedure used heat-mediated EDTA retrieval at pH 8.0; its dependence on that retrieval condition has not been established (caption: EDTA retrieval at pH 8.0). HPA shows ICC-IF images and mainly nucleoplasmic localization, but the supplied evidence does not establish whether frozen sections or IF are easier than paraffin IHC; assess kidney DAB signal against the peroxidase control (HPA: ICC-IF images and approved nucleoplasm localization; standard IHC practice).
HPA tissue IHC evidence for POU2F1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | Endocrine cells | High | Protein (IHC) | HPA → |
| Kidney | Collecting ducts | High | Protein (IHC) | HPA → |
| Placenta | Syncytiotrophoblasts - cell body | High | Protein (IHC) | HPA → |
| Rectum | Endocrine cells | High | Protein (IHC) | HPA → |
| Testis | Preleptotene spermatocytes | High | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Bronchus | Respiratory epithelial cells | Not detected | Protein (IHC) | HPA → |
| Cerebellum | Cells in granular layer | Not detected | Protein (IHC) | HPA → |
| Heart muscle | Cardiomyocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced POU2F1 IHC Tips
Troubleshoot POU2F1 staining in paraffin section IHC by checking retrieval, nuclear localisation, antibody specificity and cell type before comparing signal between samples.
How should I troubleshoot weak nuclear POU2F1 staining after antigen retrieval?
Start with heat-mediated EDTA retrieval at pH 8.0 for paraffin sections (datasheet M01766-1). The selected tissue image used this condition with 2 μg/ml primary antibody overnight at 4°C (datasheet M01766-1). If nuclear staining is weak, vary heating duration on adjacent sections while holding antibody concentration and detection constant (standard IHC practice). Compare nuclear signal and tissue morphology in breast glandular cells, which show medium staining in the reference profile (HPA: Medium in breast glandular cells; standard IHC practice). If EDTA optimisation fails, test another buffer or pH as a fallback and record its effect on morphology (standard IHC practice).
Can fixation explain variable POU2F1 nuclear staining across paraffin blocks?
Target-specific sensitivity to fixation is unknown because the selected paraffin tissue caption does not state a fixative (datasheet M01766-1). Record each block's fixative and fixation duration before comparing nuclear staining across cases (standard IHC practice). Process comparison sections with the same EDTA pH 8.0 retrieval and 2 μg/ml primary antibody conditions used in the selected image (datasheet M01766-1). If blocks differ in signal, assess preserved nuclear morphology and include a control processed with each fixation condition (standard IHC practice). Do not assign a POU2F1-specific fixation effect without a direct matched comparison; differences in processing or detection can also affect staining (standard IHC practice).
What should I do when POU2F1 staining appears mainly cytoplasmic?
Prioritise nuclear staining when reading chromogenic sections because POU2F1 is nuclear and the tissue profile reports expression in nuclei of most cells (UniProt P14859 subcellular; HPA tissue IHC). Mark cytoplasmic-only staining separately from nuclear-positive cells rather than combining them in a single score (standard IHC practice). The subcellular imaging profile also lists approved endoplasmic reticulum and vesicle locations, so cytoplasmic signal alone is not a definitive artefact (HPA subcellular). Check nuclear morphology, primary-antibody omission and the distribution across cell types before interpreting that signal (standard IHC practice). POU2F1 has no transmembrane segment, so membrane-rim staining needs independent validation before being attributed to this target (UniProt P14859 topology; standard IHC practice).
Could isoforms or modified residues change what my POU2F1 antibody detects?
POU2F1 has 6 listed isoforms, and isoform 2 is described as lymphocyte-specific (UniProt P14859 isoforms and tissue specificity). Its POU-specific domain spans residues 280–354, and recorded phosphorylation sites include residues 270, 276 and 283 (UniProt P14859 domains and modified residues). Check the antibody's mapped epitope and stated isoform coverage before attributing different cell staining to abundance alone (standard IHC practice). If those details are unavailable, compare staining with an independently validated antibody targeting another region on serial sections (standard IHC practice). Retrieval or fixation can alter epitope access in paraffin sections, but these records do not establish which POU2F1 isoforms this catalog antibody detects (standard IHC practice; datasheet M01766-1).
How can I check a disputed POU2F1 IHC pattern with multiplex IF?
Use IF as a separate check of the disputed IHC localisation: POU2F1 is nuclear, with nucleoplasm the main approved subcellular location (UniProt P14859 subcellular; HPA subcellular). Pair POU2F1 with a marker that identifies the cell population being assessed, such as a validated endocrine-cell marker when examining colon endocrine cells (HPA: High in colon endocrine cells; standard IF practice). Select fluorophores after checking the specimen's autofluorescence, and place the weaker expected signal in a cleaner channel (standard IF practice). Permeabilise sufficiently for antibody access to the nuclear epitope, since POU2F1 has no transmembrane segment (UniProt P14859 topology; standard IF practice). Include single-stain and primary-omission controls to assess channel bleed-through and background before comparing IF with DAB staining (standard IF practice).
How do I reduce diffuse DAB signal without losing POU2F1 nuclear staining?
First compare the section with a primary-antibody omission control to separate detection background from antibody-dependent staining (standard IHC practice). The selected paraffin tissue image used 10% goat serum block, 2 μg/ml primary overnight at 4°C, and DAB development (datasheet M01766-1). Include a peroxidase block before HRP detection, then inspect the omission control for residual endogenous enzyme signal (standard chromogenic IHC practice). If antibody-dependent background remains, titrate the primary below the documented concentration while retaining the same retrieval and exposure conditions (datasheet M01766-1; standard IHC practice). Judge the result by retained nuclear contrast and intact morphology, consistent with the reported predominantly nuclear tissue pattern (HPA tissue IHC; standard IHC practice).
How should I score POU2F1 IHC across heterogeneous tissue regions? ⚠ ANSWER MARKED FOR VERIFICATION
Define the cell population and analysis region before scoring, and exclude folds, necrosis and section edges (standard IHC practice). Score nuclear DAB with an H-score or report the percentage of positive nuclei within each defined cell population (standard IHC practice; HPA tissue IHC: nuclear expression in most cells). For spatial comparisons, report positive nuclear density per mm² of evaluable tissue and the total nuclei assessed (standard IHC practice). Normalise each regional result to its eligible nuclei or evaluable area, and keep the positivity threshold fixed across slides (standard IHC practice). Report cell types separately because the reference profile ranges from high staining in colon endocrine cells to no detection in adipocytes (HPA tissue IHC).
How can I distinguish true POU2F1 signal from tissue artefacts?
Look first for crisp nuclear staining: POU2F1 is nuclear, and the reference tissue profile describes nuclear expression in most cells (UniProt P14859 subcellular; HPA tissue IHC). Judge intensity within identified cell populations because colon endocrine cells are high while adipocytes are reported as not detected (HPA tissue IHC). Treat staining concentrated at cut edges or over necrotic areas cautiously, and compare intact central tissue with the same detection settings (standard IHC practice). Check a primary-omission section for endogenous peroxidase or nonspecific DAB deposition before calling weak staining positive (standard chromogenic IHC practice). The reference tissue IHC reliability is Supported with medium agreement between staining and RNA data, so confirm unexpected compartment or cell patterns independently (HPA tissue IHC; standard IHC practice).
Boster reagents
Best POU2F1 / POU domain, class 2, transcription factor 1 IHC Antibodies
Both antibodies have human tissue IHC images (M01766-1 image caption: breast cancer paraffin section; PB9317 image caption: tonsil IHC(P)); M01766-1 also lists mouse and rat reactivity (catalog reactivity).
Real IHC data
Anti-Oct-1 Rabbit Monoclonal Antibody
Cat # M01766-1
Real IHC data
Anti-Oct-1/POU2F1 Antibody ®
Cat # PB9317
M01766-1 will render with an IHC image from a human breast cancer paraffin section (M01766-1 image caption). PB9317 will render with a human tonsil IHC(P) image (PB9317 image caption).
Which to pick: For tissue IHC, M01766-1 is a rabbit monoclonal with a human breast cancer paraffin-section example; PB9317 has a human tonsil IHC(P) example (catalog clone and host; respective image captions). For mouse or rat samples, M01766-1 lists those species, although its supplied IHC images show human tissue (catalog reactivity; M01766-1 image captions). Neither SKU lists IF/ICC or provides an IF image, and neither IHC caption reports the fixative (catalog applications and IF image alts; respective IHC image captions).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P14859 (PO2F1_HUMAN, POU domain, class 2, transcription factor 1).
- Human Protein Atlas. POU2F1 tissue IHC expression (reliability: Supported).
- Human Protein Atlas. POU2F1 subcellular location (ICC-IF): Mainly localized to the nucleoplasm. In addition localized to the endoplasmic reticulum and vesicles..
- Human Protein Atlas. POU2F1 antibody validation summary (4 antibodies).
- Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy. Cell death discovery 2026 — PMC13168495.
- High expression of transcription factor POU2F1 confers improved survival on smokers with lung adenocarcinoma: a retrospective study of two cohorts. Translational lung cancer research 2023 — PMC10183409.
- POU2F1 promotes hypertensive cardiac fibrosis by regulating mitochondrial homeostasis through PINK1/Parkin‑dependent mitophagy. Molecular medicine reports 2026 — PMC13543148.
- Isoimperatorin suppresses triple-negative breast cancer by modulating miR-874-3p/POU2F1 axis: a new avenue for metabolic and redox intervention. Biological research 2026 — PMC13097874.
- PubMed PMID:2905684 — UniProt-cited evidence.
- PubMed PMID:12663137 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for POU2F1 (POU domain, class 2, transcription factor 1). Expected localisation Nuclear staining in most cells (HPA tissue IHC). Antigen retrieval: EDTA pH 8.0 HIER, heat-mediated (datasheet M01766-1). Validated IHC antibody: M01766-1 at 1:50 recommended; image 2 μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Colon (Endocrine cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human breast cancer tissue; fixative not specified (datasheet M01766-1); 2. Fixation: Image fixative and duration unreported (datasheet M01766-1); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: EDTA pH 8.0 (datasheet M01766-1); 20 min, 95–100 °C (standard); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet M01766-1); 8. Primary antibody: Rabbit monoclonal (clone 19P20) anti-POU2F1, 1:50 recommended; image 2 μg/ml (datasheet M01766-1); 9. Primary incubation: Overnight at 4 °C (datasheet M01766-1). Watch for: Fixation: Keep fixation consistent across sections (standard IHC practice; not target-specific); Caveat: Adipocytes have no detectable staining (HPA tissue IHC); Isoform / epitope: 6 isoforms; verify epitope coverage across variants (UniProt); Regulation: Isoform 2 is lymphocyte-specific (UniProt). Evidence: UniProt P14859, HPA tissue IHC · Supported, HPA ICC-IF · Mainly localized to the nucleoplasm. In addition localized to the…, Datasheet M01766-1, PMC10183409, PMC13543148. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/POU2F1/immunohistochemistry-ihc-guide.